Research programme: anti-inflammatory antibodies - NovImmune/Tiziana

Drug Profile

Research programme: anti-inflammatory antibodies - NovImmune/Tiziana

Alternative Names: NI-1201; NI-1201/α-IL-6Rc

Latest Information Update: 05 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NovImmune SA
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 03 Jan 2017 Tiziana Life Sciences in-licenses NI 1201 from Novimmune
  • 19 Feb 2014 Preclinical development is ongoing in Europe
  • 28 Nov 2012 A compound from this programme (NI 0101) was advanced into clinical development [see separate profile]
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top